Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
2007

Poxvirus Vaccine for Advanced Pancreatic Cancer

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): Howard L Kaufman, Seunghee Kim-Schulze, Kelledy Manson, Gail DeRaffele, Josephine Mitcham, Kang Seok Seo, Dae Won Kim, John Marshall

Primary Institution: Columbia University

Hypothesis

Can a poxvirus-based vaccine improve immune response and survival in patients with advanced pancreatic cancer?

Conclusion

Poxvirus vaccination is safe, well tolerated, and capable of generating antigen-specific immune responses in patients with advanced pancreatic cancer.

Supporting Evidence

  • All patients developed antibody responses against vaccinia virus.
  • 62.5% of evaluable patients showed antigen-specific T cell responses.
  • Median overall survival was significantly longer in patients with immune responses.

Takeaway

This study tested a new vaccine for pancreatic cancer and found it to be safe and able to help the immune system fight the cancer.

Methodology

Ten patients received a prime-boost vaccination regimen with poxviruses expressing tumor antigens and costimulatory molecules, followed by immune analysis.

Potential Biases

Potential bias due to the small number of patients and lack of a control group.

Limitations

The study had a small sample size and was not designed to detect clinical responses.

Participant Demographics

Patients were predominantly Caucasian, with a mean age of 57.9 years, and most had metastatic disease.

Statistical Information

P-Value

0.002

Statistical Significance

p = .002

Digital Object Identifier (DOI)

10.1186/1479-5876-5-60

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication